Niki BioSolutions, Inc. (NIKI) Stock Score, Valuation & Financial Research

Niki BioSolutions, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NIKI

Niki BioSolutions, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.60. These figures are a research snapshot, not a buy or sell recommendation.

What Niki BioSolutions, Inc. does

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Niki BioSolutions operates as a biotechnology company focused on the research and development of therapeutic and diagnostic solutions. The company generates revenue primarily through the commercialization of diagnostic services, such as Alzheimer's disease blood tests, and seeks to fund its operations through capital market activities and strategic mergers.

Products and services

  • The company provides diagnostic testing services, specifically focusing on Alzheimer's disease blood-based diagnostics, and maintains a pipeline of preclinical and clinical-stage therapeutic candidates.

Customer types

Healthcare providers; Clinical research institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct preclinical studies and clinical trials. Source

Business relationships and partnerships

  • Fios Genomics — A strategic partnership focused on bioinformatics and statistical analysis to accelerate the company's Alzheimer's disease testing pipeline. Source
  • DiamiR Biosciences Corp. — A merger agreement involving a 70/30 split to integrate diagnostic capabilities and expand the company's service offerings. Source

Business strengths to evaluate

  • Specialized focus on Alzheimer's disease diagnostics Source

Business risks and research considerations

  • Going concern uncertainty Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source · Fios Genomics · DiamiR Biosciences Corp. · Going concern uncertainty

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NIKI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.60
Market capitalization:
374.61K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -2.28M
Free cash flow:
USD -1.84M
Cash:
USD 3.45M
Total debt:
USD 3.44M
EPS:
USD -33.50

What stands out

  • Free cash flow is USD -1.84M, negative for the stored period.
  • The balance sheet shows USD 3.45M of cash versus USD 3.44M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.96K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NIKI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NIKI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does NIKI's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for NIKI to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NIKI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NIKI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.